首页 > 最新文献

Seminars in cancer biology最新文献

英文 中文
Cancer prevention and interception with antidiabetic and anti-obesity drugs: Current and future perspectives 用抗糖尿病和抗肥胖药物预防和阻断癌症:当前和未来的观点。
IF 15.7 1区 医学 Q1 ONCOLOGY Pub Date : 2025-07-21 DOI: 10.1016/j.semcancer.2025.07.008
Adriana Albini , Anna Rita Cantelmo , Lorenzo Mortara , Douglas M. Noonan , Giovanni Corso
Obesity and type 2 diabetes are major risk factors for cardiovascular diseases and multiple malignancies, and epidemiology reveals an increasing burden of obesity-related cancers, in particular liver, pancreatic and endometrial. Obesity is also clearly associated with an increased risk of breast cancer, particularly in postmenopausal women. Chronic hyperinsulinemia, systemic inflammation, and metabolic dysregulation create a tumor-promoting environment, emphasizing the need for interventions that target metabolic health and can provide cancer prevention or interception. This review examines the potential cancer-preventive effects of antidiabetic and anti-obesity drugs, summarizing current preclinical and clinical evidence on their mechanisms and efficacy. Among these agents, metformin has been extensively studied, demonstrating anticancer properties through AMP-activated protein kinase activation, mammalian target of rapamycin inhibition, and reduced insulin-like growth factor 1 signaling. Glucagon-like peptide-1 receptor agonists, including semaglutide and tirzepatide, promote weight loss, insulin sensitivity, and anti-inflammatory effects, with emerging evidence suggesting direct tumor-suppressive actions. Sodium-glucose cotransporter 2 inhibitors modulate tumor metabolism by reducing glucose availability and mitigating systemic inflammation. Other agents, including dipeptidyl peptidase-4 inhibitors, thiazolidinediones, sulfonylureas, and alpha-glucosidase inhibitors, have shown mixed evidence regarding their potential anticancer effects, necessitating further investigation. While observational studies and meta-analyses suggest a potential reduction in cancer risk with certain antidiabetic and anti-obesity agents, randomized controlled trials specifically assessing cancer prevention are limited. Additionally, long-term safety concerns, including potential tumor-promoting effects in specific contexts, warrant further investigation. Future research should focus on large-scale clinical trials and mechanistic studies to validate the oncologic benefits and risks of these agents.
肥胖和2型糖尿病是心血管疾病和多种恶性肿瘤的主要危险因素,流行病学显示,肥胖相关癌症的负担日益增加,特别是肝脏、胰腺和子宫内膜癌。肥胖也明显与乳腺癌风险增加有关,尤其是绝经后妇女。慢性高胰岛素血症、全身性炎症和代谢失调创造了促进肿瘤的环境,强调了针对代谢健康的干预措施的必要性,并可以提供癌症预防或阻断。本文综述了抗糖尿病和抗肥胖药物的潜在癌症预防作用,总结了目前关于其机制和疗效的临床前和临床证据。在这些药物中,二甲双胍已被广泛研究,通过amp激活的蛋白激酶激活、哺乳动物雷帕霉素抑制靶点和减少胰岛素样生长因子1信号传导显示抗癌特性。胰高血糖素样肽-1受体激动剂,包括西马鲁肽和替西肽,可促进体重减轻、胰岛素敏感性和抗炎作用,新出现的证据表明其具有直接的肿瘤抑制作用。钠-葡萄糖共转运蛋白2抑制剂通过降低葡萄糖可用性和减轻全身炎症来调节肿瘤代谢。其他药物,包括二肽基肽酶-4抑制剂、噻唑烷二酮类、磺脲类和α -葡萄糖苷酶抑制剂,已显示出其潜在抗癌作用的混合证据,需要进一步研究。虽然观察性研究和荟萃分析表明,某些抗糖尿病和抗肥胖药物可能降低癌症风险,但专门评估癌症预防的随机对照试验有限。此外,长期的安全性问题,包括在特定情况下潜在的促肿瘤作用,值得进一步研究。未来的研究应该集中在大规模的临床试验和机制研究上,以验证这些药物的肿瘤益处和风险。
{"title":"Cancer prevention and interception with antidiabetic and anti-obesity drugs: Current and future perspectives","authors":"Adriana Albini ,&nbsp;Anna Rita Cantelmo ,&nbsp;Lorenzo Mortara ,&nbsp;Douglas M. Noonan ,&nbsp;Giovanni Corso","doi":"10.1016/j.semcancer.2025.07.008","DOIUrl":"10.1016/j.semcancer.2025.07.008","url":null,"abstract":"<div><div>Obesity and type 2 diabetes are major risk factors for cardiovascular diseases and multiple malignancies, and epidemiology reveals an increasing burden of obesity-related cancers, in particular liver, pancreatic and endometrial. Obesity is also clearly associated with an increased risk of breast cancer, particularly in postmenopausal women. Chronic hyperinsulinemia, systemic inflammation, and metabolic dysregulation create a tumor-promoting environment, emphasizing the need for interventions that target metabolic health and can provide cancer prevention or interception. This review examines the potential cancer-preventive effects of antidiabetic and anti-obesity drugs, summarizing current preclinical and clinical evidence on their mechanisms and efficacy. Among these agents, metformin has been extensively studied, demonstrating anticancer properties through AMP-activated protein kinase activation, mammalian target of rapamycin inhibition, and reduced insulin-like growth factor 1 signaling. Glucagon-like peptide-1 receptor agonists, including semaglutide and tirzepatide, promote weight loss, insulin sensitivity, and anti-inflammatory effects, with emerging evidence suggesting direct tumor-suppressive actions. Sodium-glucose cotransporter 2 inhibitors modulate tumor metabolism by reducing glucose availability and mitigating systemic inflammation. Other agents, including dipeptidyl peptidase-4 inhibitors, thiazolidinediones, sulfonylureas, and alpha-glucosidase inhibitors, have shown mixed evidence regarding their potential anticancer effects, necessitating further investigation. While observational studies and meta-analyses suggest a potential reduction in cancer risk with certain antidiabetic and anti-obesity agents, randomized controlled trials specifically assessing cancer prevention are limited. Additionally, long-term safety concerns, including potential tumor-promoting effects in specific contexts, warrant further investigation. Future research should focus on large-scale clinical trials and mechanistic studies to validate the oncologic benefits and risks of these agents.</div></div>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":"115 ","pages":"Pages 40-52"},"PeriodicalIF":15.7,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144699378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of deiodinases on metabolic alteration in cancer 脱碘酶在癌症代谢改变中的作用。
IF 12.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-07-10 DOI: 10.1016/j.semcancer.2025.07.003
Caterina Miro , Annunziata Gaetana Cicatiello , Monica Dentice , Annarita Nappi
Deiodinases are key regulators of Thyroid Hormone (TH) bioavailability, exerting a precise spatial and temporal control over T3 levels in peripheral tissues. By dynamically modulating TH activation and inactivation, deiodinases allow target organs to adapt TH signaling to physiological and pathological demands, highlighting their importance in both health and disease. In cancer, their dysregulated expression reprograms cellular metabolism and shapes the tumor microenvironment (TME). Type 3 deiodinase (D3), frequently upregulated in proliferative and hypoxic tumor regions, fosters cell proliferation and resistance to differentiation. Conversely, type 2 deiodinase (D2) sustains glycolytic metabolism, angiogenesis, and redox disbalance, particularly in aggressive and p53-deficient tumors. Beyond cancer cells, deiodinases activity influences stromal and immune compartments, impacting glutamine metabolism and immune cell plasticity. This complex endocrine-metabolic axis supports tumor adaptation to stress and contributes to the emergence of resistance to therapy. Recent advances reveal the potential of targeting deiodinases to counteract cancer metabolic reprogramming and re-sensitize tumors to treatment. Given the essential and multifaceted roles of deiodinases in cancer biology, a comprehensive understanding of their mechanisms of action, regulation, and clinical implications is critical. This review aims to summarize current knowledge on the roles of deiodinases in cancer metabolism and immunity, focusing on their biochemical properties, regulatory networks, tissue-specific functions, and contributions to disease. In doing so, we seek to highlight emerging concepts in local TH signaling and explore potential avenues for therapeutic intervention targeting deiodinase pathways in precision oncology.
脱碘酶是甲状腺激素(TH)生物利用度的关键调节因子,对外周组织中T3水平施加精确的时空控制。通过动态调节TH的激活和失活,脱碘酶允许目标器官适应生理和病理需求的TH信号,突出了它们在健康和疾病中的重要性。在癌症中,它们的失调表达重编程细胞代谢并塑造肿瘤微环境(TME)。3型脱碘酶(D3),在增殖和缺氧肿瘤区域经常上调,促进细胞增殖和分化抵抗。相反,2型脱碘酶(D2)维持糖酵解代谢、血管生成和氧化还原失衡,特别是在侵袭性和p53缺乏的肿瘤中。除癌细胞外,脱碘酶活性还影响基质和免疫室,影响谷氨酰胺代谢和免疫细胞的可塑性。这种复杂的内分泌代谢轴支持肿瘤对压力的适应,并有助于对治疗产生耐药性。最近的进展揭示了靶向去碘酶对抗癌症代谢重编程和使肿瘤对治疗再敏感的潜力。鉴于脱碘酶在癌症生物学中的重要和多方面的作用,全面了解它们的作用机制、调节和临床意义是至关重要的。本文综述了脱碘酶在肿瘤代谢和免疫中的作用,重点介绍了它们的生化特性、调节网络、组织特异性功能和对疾病的贡献。在此过程中,我们试图突出局部TH信号的新兴概念,并探索精准肿瘤学中针对脱碘酶途径的治疗干预的潜在途径。
{"title":"The role of deiodinases on metabolic alteration in cancer","authors":"Caterina Miro ,&nbsp;Annunziata Gaetana Cicatiello ,&nbsp;Monica Dentice ,&nbsp;Annarita Nappi","doi":"10.1016/j.semcancer.2025.07.003","DOIUrl":"10.1016/j.semcancer.2025.07.003","url":null,"abstract":"<div><div>Deiodinases are key regulators of Thyroid Hormone (TH) bioavailability, exerting a precise spatial and temporal control over T3 levels in peripheral tissues. By dynamically modulating TH activation and inactivation, deiodinases allow target organs to adapt TH signaling to physiological and pathological demands, highlighting their importance in both health and disease. In cancer, their dysregulated expression reprograms cellular metabolism and shapes the tumor microenvironment (TME). Type 3 deiodinase (D3), frequently upregulated in proliferative and hypoxic tumor regions, fosters cell proliferation and resistance to differentiation. Conversely, type 2 deiodinase (D2) sustains glycolytic metabolism, angiogenesis, and redox disbalance, particularly in aggressive and p53-deficient tumors. Beyond cancer cells, deiodinases activity influences stromal and immune compartments, impacting glutamine metabolism and immune cell plasticity. This complex endocrine-metabolic axis supports tumor adaptation to stress and contributes to the emergence of resistance to therapy. Recent advances reveal the potential of targeting deiodinases to counteract cancer metabolic reprogramming and re-sensitize tumors to treatment. Given the essential and multifaceted roles of deiodinases in cancer biology, a comprehensive understanding of their mechanisms of action, regulation, and clinical implications is critical. This review aims to summarize current knowledge on the roles of deiodinases in cancer metabolism and immunity, focusing on their biochemical properties, regulatory networks, tissue-specific functions, and contributions to disease. In doing so, we seek to highlight emerging concepts in local TH signaling and explore potential avenues for therapeutic intervention targeting deiodinase pathways in precision oncology.</div></div>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":"114 ","pages":"Pages 215-226"},"PeriodicalIF":12.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144619968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research PDAC中的CRISPR/Cas9基因组工程:从临床前研究到翻译和临床研究
IF 12.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-07-10 DOI: 10.1016/j.semcancer.2025.07.004
Yanxi Lu , Jojanneke Stoof , Yaba Rosette Tanoé , Naomi Walsh , Maarten F. Bijlsma , Huijun Lei , Tianhui Chen , Jelena Grahovac , Robert Grützmann , Christian Pilarsky
CRISPR/Cas9 technology has emerged as a powerful tool in pancreatic ductal adenocarcinoma cancer (PDAC) research, facilitating the study of genes involved in cell signaling pathways, proliferation, migration, invasion, and chemotherapy resistance. In this review, we discuss the evolution of CRISPR technologies from sophisticated editing techniques to broad screening methods, examine the utility of isogenic models and genetically engineered mouse models (GEMMs). We also explore how CRISPR/Cas9 screens can reveal immune-tumor cell interactions, highlighting the multifaceted role of this technology in PDAC research. Moreover, we emphasize the use of CRISPR technology in diagnostics for CAR-T cell therapies, where CRISPR/Cas9 enhances the precision of targeting malignant cells while minimizing off-tumor effects.
CRISPR/Cas9技术已成为胰腺导管腺癌(pancreatic ductal adenocarcinoma cancer, PDAC)研究的有力工具,促进了对细胞信号通路、增殖、迁移、侵袭、化疗耐药等相关基因的研究。在这篇综述中,我们讨论了CRISPR技术从复杂的编辑技术到广泛的筛选方法的演变,研究了等基因模型和基因工程小鼠模型(GEMMs)的实用性。我们还探讨了CRISPR/Cas9筛选如何揭示免疫肿瘤细胞相互作用,突出了该技术在PDAC研究中的多方面作用。此外,我们强调在CAR-T细胞治疗的诊断中使用CRISPR技术,其中CRISPR/Cas9提高了靶向恶性细胞的精度,同时最大限度地减少了非肿瘤效应。
{"title":"CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research","authors":"Yanxi Lu ,&nbsp;Jojanneke Stoof ,&nbsp;Yaba Rosette Tanoé ,&nbsp;Naomi Walsh ,&nbsp;Maarten F. Bijlsma ,&nbsp;Huijun Lei ,&nbsp;Tianhui Chen ,&nbsp;Jelena Grahovac ,&nbsp;Robert Grützmann ,&nbsp;Christian Pilarsky","doi":"10.1016/j.semcancer.2025.07.004","DOIUrl":"10.1016/j.semcancer.2025.07.004","url":null,"abstract":"<div><div>CRISPR/Cas9 technology has emerged as a powerful tool in pancreatic ductal adenocarcinoma cancer (PDAC) research, facilitating the study of genes involved in cell signaling pathways, proliferation, migration, invasion, and chemotherapy resistance. In this review, we discuss the evolution of CRISPR technologies from sophisticated editing techniques to broad screening methods, examine the utility of isogenic models and genetically engineered mouse models (GEMMs). We also explore how CRISPR/Cas9 screens can reveal immune-tumor cell interactions, highlighting the multifaceted role of this technology in PDAC research. Moreover, we emphasize the use of CRISPR technology in diagnostics for CAR-T cell therapies, where CRISPR/Cas9 enhances the precision of targeting malignant cells while minimizing off-tumor effects.</div></div>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":"114 ","pages":"Pages 242-255"},"PeriodicalIF":12.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144619967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of sarcopenic obesity on cancer clinical outcomes 肌肉减少型肥胖对癌症临床结果的影响
IF 12.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-07-08 DOI: 10.1016/j.semcancer.2025.07.002
Bahadır Köylü , Cem Sulu , Volkan Demirhan Yumuk , Perran Fulden Yumuk
Sarcopenic obesity is a distinct clinical condition characterized by the coexistence of excess fat and reduced muscle mass. Although the prevalence of sarcopenic obesity varies depending on the definition used, it is increasingly recognized as a significant health concern, regardless of age and underlying disease. Despite limited understanding of the crosstalk between sarcopenic obesity and cancer, emerging evidence suggests that sarcopenic obesity not only promotes a metabolic and inflammatory environment conducive to cancer progression but also profoundly impacts treatment efficacy, safety, and survival outcomes. This review provides a concise overview of the key aspects of sarcopenic obesity, with a particular focus on its role in the cancer setting. We also assess existing evidence on its influence on oncological outcomes in both early and advanced stages of the various solid tumor types.
肌少性肥胖是一种独特的临床病症,其特征是脂肪过多和肌肉质量减少并存。尽管肌少性肥胖的流行程度因使用的定义而异,但它越来越被认为是一个重要的健康问题,与年龄和潜在疾病无关。尽管对肌少性肥胖和癌症之间的相互关系了解有限,但新出现的证据表明,肌少性肥胖不仅促进了有利于癌症进展的代谢和炎症环境,而且深刻影响了治疗的有效性、安全性和生存结果。这篇综述简要概述了肌肉减少性肥胖的关键方面,特别关注其在癌症环境中的作用。我们还评估了其对各种实体瘤类型早期和晚期肿瘤预后影响的现有证据。
{"title":"The impact of sarcopenic obesity on cancer clinical outcomes","authors":"Bahadır Köylü ,&nbsp;Cem Sulu ,&nbsp;Volkan Demirhan Yumuk ,&nbsp;Perran Fulden Yumuk","doi":"10.1016/j.semcancer.2025.07.002","DOIUrl":"10.1016/j.semcancer.2025.07.002","url":null,"abstract":"<div><div>Sarcopenic obesity is a distinct clinical condition characterized by the coexistence of excess fat and reduced muscle mass. Although the prevalence of sarcopenic obesity varies depending on the definition used, it is increasingly recognized as a significant health concern, regardless of age and underlying disease. Despite limited understanding of the crosstalk between sarcopenic obesity and cancer, emerging evidence suggests that sarcopenic obesity not only promotes a metabolic and inflammatory environment conducive to cancer progression but also profoundly impacts treatment efficacy, safety, and survival outcomes. This review provides a concise overview of the key aspects of sarcopenic obesity, with a particular focus on its role in the cancer setting. We also assess existing evidence on its influence on oncological outcomes in both early and advanced stages of the various solid tumor types.</div></div>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":"114 ","pages":"Pages 203-214"},"PeriodicalIF":12.1,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144588547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From awareness to action: Revolutionizing cardio-oncology in China 从意识到行动:革新中国的心脏肿瘤学
IF 12.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-07-07 DOI: 10.1016/j.semcancer.2025.06.011
Aman Wang, Jiwei Liu
Cardio-oncology is an emerging interdisciplinary field focused on the intersection of cancer and cardiovascular disease. With the rising incidence of both cancer and cardiovascular disease in China, establishing a strong cardio-oncology framework has become essential. This review examines the historical development, clinical practices, and key milestones of cardio-oncology in China, emphasizing the importance of multidisciplinary teams, specialized guidelines, and international collaborations. Additionally, it discusses the current challenges and future opportunities for advancing cardio-oncology within China’s healthcare landscape.
心脏肿瘤学是一个新兴的跨学科领域,专注于癌症和心血管疾病的交叉。随着中国癌症和心血管疾病的发病率不断上升,建立一个强有力的心脏肿瘤学框架已变得至关重要。本文回顾了中国心脏肿瘤学的历史发展、临床实践和关键里程碑,强调了多学科团队、专业指南和国际合作的重要性。此外,它还讨论了在中国医疗保健领域推进心脏肿瘤学的当前挑战和未来机遇。
{"title":"From awareness to action: Revolutionizing cardio-oncology in China","authors":"Aman Wang,&nbsp;Jiwei Liu","doi":"10.1016/j.semcancer.2025.06.011","DOIUrl":"10.1016/j.semcancer.2025.06.011","url":null,"abstract":"<div><div>Cardio-oncology is an emerging interdisciplinary field focused on the intersection of cancer and cardiovascular disease. With the rising incidence of both cancer and cardiovascular disease in China, establishing a strong cardio-oncology framework has become essential. This review examines the historical development, clinical practices, and key milestones of cardio-oncology in China, emphasizing the importance of multidisciplinary teams, specialized guidelines, and international collaborations. Additionally, it discusses the current challenges and future opportunities for advancing cardio-oncology within China’s healthcare landscape.</div></div>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":"114 ","pages":"Pages 195-202"},"PeriodicalIF":12.1,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144588546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reopening Pandora’s box: Is there a role for HDL in breast cancer? 重新打开潘多拉的盒子:高密度脂蛋白在乳腺癌中有作用吗?
IF 12.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-07-05 DOI: 10.1016/j.semcancer.2025.07.001
Maria Isabela Bloise Alves Caldas Sawada , Monique de Fatima de Mello Santana , Milena Gomes Vancini , Marisa Passarelli
Plasma lipid and lipoprotein profiles are recognized as key modulators in breast cancer (BC) development. Notably, the association between high-density lipoprotein cholesterol (HDLc) and BC remains controversial, with studies reporting positive, negative, or no correlation. This inconsistency may arise from the clinical metrics used to quantify high-density lipoproteins (HDL), such as HDLc and apolipoprotein (apo) A-1, which may not accurately reflect HDL functionality in modulating the tumor microenvironment. Moreover, HDL particles isolated from plasma may undergo modifications influenced by tumor activity, varying with disease stage, severity, and treatment. In this review, we are critically reopening Pandora´s box analyzing evidence on HDLc plasma levels and HDL functionality in BC. Specifically, HDL contributes to tumor regulation by removing excess cellular cholesterol, thereby limiting sterol availability for cell replication and metastasis. Additionally, HDL exerts antioxidant and anti-inflammatory effects and acts as a carrier of bioactive proteins, lipids, and microRNAs, facilitating their delivery to target cells and modulating intracellular signaling and gene expression. Collectively, HDL functionality may serve as a predictor of therapeutic response and clinical outcomes in BC.
血浆脂质和脂蛋白谱被认为是乳腺癌(BC)发展的关键调节因子。值得注意的是,高密度脂蛋白胆固醇(HDLc)与BC之间的关系仍然存在争议,研究报告呈正相关、负相关或无相关。这种不一致可能是由于用于量化高密度脂蛋白(HDL)的临床指标,如HDL和载脂蛋白A-1,可能不能准确反映HDL在调节肿瘤微环境中的功能。此外,从血浆中分离出的HDL颗粒可能受到肿瘤活性的影响,随疾病分期、严重程度和治疗而变化。在这篇综述中,我们重新打开潘多拉的盒子,分析BC患者HDL血浆水平和HDL功能的证据。具体来说,HDL通过去除多余的细胞胆固醇来调节肿瘤,从而限制了细胞复制和转移的固醇可用性。此外,HDL具有抗氧化和抗炎作用,并作为生物活性蛋白、脂质和microrna的载体,促进其递送到靶细胞并调节细胞内信号传导和基因表达。总的来说,HDL功能可以作为BC治疗反应和临床结果的预测因子。
{"title":"Reopening Pandora’s box: Is there a role for HDL in breast cancer?","authors":"Maria Isabela Bloise Alves Caldas Sawada ,&nbsp;Monique de Fatima de Mello Santana ,&nbsp;Milena Gomes Vancini ,&nbsp;Marisa Passarelli","doi":"10.1016/j.semcancer.2025.07.001","DOIUrl":"10.1016/j.semcancer.2025.07.001","url":null,"abstract":"<div><div>Plasma lipid and lipoprotein profiles are recognized as key modulators in breast cancer (BC) development. Notably, the association between high-density lipoprotein cholesterol (HDLc) and BC remains controversial, with studies reporting positive, negative, or no correlation. This inconsistency may arise from the clinical metrics used to quantify high-density lipoproteins (HDL), such as HDLc and apolipoprotein (apo) A-1, which may not accurately reflect HDL functionality in modulating the tumor microenvironment. Moreover, HDL particles isolated from plasma may undergo modifications influenced by tumor activity, varying with disease stage, severity, and treatment. In this review, we are critically reopening Pandora´s box analyzing evidence on HDLc plasma levels and HDL functionality in BC. Specifically, HDL contributes to tumor regulation by removing excess cellular cholesterol, thereby limiting sterol availability for cell replication and metastasis. Additionally, HDL exerts antioxidant and anti-inflammatory effects and acts as a carrier of bioactive proteins, lipids, and microRNAs, facilitating their delivery to target cells and modulating intracellular signaling and gene expression. Collectively, HDL functionality may serve as a predictor of therapeutic response and clinical outcomes in BC.</div></div>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":"114 ","pages":"Pages 227-241"},"PeriodicalIF":12.1,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy 肠道菌群调节增强免疫检查点抑制剂疗效的研究进展及机制。
IF 12.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-07-03 DOI: 10.1016/j.semcancer.2025.06.012
Li Chen , Baoyi Li , Menghang Zu , Rui L. Reis , Subhas C. Kundu , Bo Xiao
The gut microbiota is crucial for maintaining human health by regulating immune homeostasis and metabolic function. Immune checkpoint inhibitors (ICIs) have emerged as a cornerstone of cancer immunotherapy, yet their effectiveness is often hampered by treatment resistance and immune-related adverse events (irAEs). Increasing evidence highlights gut microbiota as a critical determinant of ICI efficacy. Here, we summarize the advances from preclinical mouse models and clinical trials to systematically illustrate how gut microbiota modulation strategies, such as fecal microbiota transplantation, specific microorganism supplementation, dietary and lifestyle interventions, and prebiotic/postbiotic supplementation, can enhance ICI therapeutic outcomes and mitigate irAEs. Mechanistically, the gut microbiota shape host immune responses, influencing innate, adaptive, and mucosal immunity, as well as immune checkpoint expression, through microbial translocation, microbiota-derived metabolites, and extracellular vesicles. This review elucidates the intricate interplay between gut microbiota and ICI treatment responses, laying a theoretical groundwork for developing personalized microbiota-based strategies to optimize cancer immunotherapy.
肠道菌群通过调节免疫稳态和代谢功能,对维持人体健康至关重要。免疫检查点抑制剂(ICIs)已成为癌症免疫治疗的基石,但其有效性往往受到治疗耐药性和免疫相关不良事件(irAEs)的阻碍。越来越多的证据表明,肠道微生物群是ICI疗效的关键决定因素。在这里,我们总结了临床前小鼠模型和临床试验的进展,以系统地说明肠道微生物群调节策略,如粪便微生物群移植、特定微生物补充、饮食和生活方式干预以及益生元/益生后补充,如何提高ICI治疗效果并减轻irAEs。从机制上讲,肠道微生物群通过微生物易位、微生物群衍生代谢物和细胞外囊泡塑造宿主免疫反应,影响先天免疫、适应性免疫和粘膜免疫,以及免疫检查点表达。这篇综述阐明了肠道微生物群与ICI治疗反应之间复杂的相互作用,为开发个性化的基于微生物群的策略来优化癌症免疫治疗奠定了理论基础。
{"title":"Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy","authors":"Li Chen ,&nbsp;Baoyi Li ,&nbsp;Menghang Zu ,&nbsp;Rui L. Reis ,&nbsp;Subhas C. Kundu ,&nbsp;Bo Xiao","doi":"10.1016/j.semcancer.2025.06.012","DOIUrl":"10.1016/j.semcancer.2025.06.012","url":null,"abstract":"<div><div>The gut microbiota is crucial for maintaining human health by regulating immune homeostasis and metabolic function. Immune checkpoint inhibitors (ICIs) have emerged as a cornerstone of cancer immunotherapy, yet their effectiveness is often hampered by treatment resistance and immune-related adverse events (irAEs). Increasing evidence highlights gut microbiota as a critical determinant of ICI efficacy. Here, we summarize the advances from preclinical mouse models and clinical trials to systematically illustrate how gut microbiota modulation strategies, such as fecal microbiota transplantation, specific microorganism supplementation, dietary and lifestyle interventions, and prebiotic/postbiotic supplementation, can enhance ICI therapeutic outcomes and mitigate irAEs. Mechanistically, the gut microbiota shape host immune responses, influencing innate, adaptive, and mucosal immunity, as well as immune checkpoint expression, through microbial translocation, microbiota-derived metabolites, and extracellular vesicles. This review elucidates the intricate interplay between gut microbiota and ICI treatment responses, laying a theoretical groundwork for developing personalized microbiota-based strategies to optimize cancer immunotherapy.</div></div>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":"114 ","pages":"Pages 150-172"},"PeriodicalIF":12.1,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating the weight: The impact of obesity on gastrointestinal cancer surgery and strategies for improved outcomes 导航体重:肥胖对胃肠癌手术的影响和改善结果的策略
IF 12.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-06-26 DOI: 10.1016/j.semcancer.2025.06.010
Gerardo Sarno , Claudia Reytor-González , Evelyn Frias-Toral , Martín Campuzano-Donoso , Christos S. Katsanos , Daniel Simancas-Racines
Obesity significantly affects gastrointestinal cancer surgery outcomes by creating complex challenges throughout the preoperative, intraoperative, and postoperative stages. This narrative review explores the intricate relationship between obesity and GIC surgery, highlighting the dual burden of obesity as a global public health issue and a determinant of surgical complications. The review aims to analyze physiological and technical hurdles, including limited visibility, prolonged operative times, increased perioperative risks, and adverse recovery outcomes associated with obesity. Evidence emphasizes the critical role of excess visceral fat, systemic inflammation, and insulin resistance in elevating surgical risks. Mitigation strategies involve preoperative nutritional optimization, use of advanced surgical technologies such as robotic-assisted and laparoscopic systems, and individualized postoperative care, encompassing early mobilization, tailored pain management, and close monitoring of metabolic parameters. Despite advancements, knowledge gaps remain, particularly regarding sarcopenic obesity and the long-term impact of preoperative dietary interventions. Future research should focus on refining minimally invasive techniques, integrating personalized medicine, and exploring innovative perioperative protocols to address obesity-related risks effectively. By fostering a multidisciplinary approach, this review underscores the necessity for targeted interventions to enhance outcomes and improve the quality of care for patients with obesity undergoing gastrointestinal cancer surgery.
肥胖通过在术前、术中和术后阶段制造复杂的挑战,显著影响胃肠道肿瘤手术结果。这篇叙述性综述探讨了肥胖和GIC手术之间的复杂关系,强调了肥胖作为全球公共卫生问题和手术并发症决定因素的双重负担。该综述旨在分析与肥胖相关的生理和技术障碍,包括能见度有限、手术时间延长、围手术期风险增加和不良恢复结果。证据强调内脏脂肪过多、全身性炎症和胰岛素抵抗在增加手术风险中的关键作用。缓解策略包括术前营养优化,使用先进的手术技术,如机器人辅助和腹腔镜系统,以及个性化的术后护理,包括早期活动,量身定制的疼痛管理和密切监测代谢参数。尽管取得了进展,但知识差距仍然存在,特别是关于肌肉减少性肥胖和术前饮食干预的长期影响。未来的研究应侧重于改进微创技术,整合个性化医疗,探索创新的围手术期方案,以有效解决肥胖相关风险。通过培养多学科的方法,本综述强调有针对性的干预措施的必要性,以提高结果和改善治疗质量的肥胖患者接受胃肠道肿瘤手术。
{"title":"Navigating the weight: The impact of obesity on gastrointestinal cancer surgery and strategies for improved outcomes","authors":"Gerardo Sarno ,&nbsp;Claudia Reytor-González ,&nbsp;Evelyn Frias-Toral ,&nbsp;Martín Campuzano-Donoso ,&nbsp;Christos S. Katsanos ,&nbsp;Daniel Simancas-Racines","doi":"10.1016/j.semcancer.2025.06.010","DOIUrl":"10.1016/j.semcancer.2025.06.010","url":null,"abstract":"<div><div>Obesity significantly affects gastrointestinal cancer surgery outcomes by creating complex challenges throughout the preoperative, intraoperative, and postoperative stages. This narrative review explores the intricate relationship between obesity and GIC surgery, highlighting the dual burden of obesity as a global public health issue and a determinant of surgical complications. The review aims to analyze physiological and technical hurdles, including limited visibility, prolonged operative times, increased perioperative risks, and adverse recovery outcomes associated with obesity. Evidence emphasizes the critical role of excess visceral fat, systemic inflammation, and insulin resistance in elevating surgical risks. Mitigation strategies involve preoperative nutritional optimization, use of advanced surgical technologies such as robotic-assisted and laparoscopic systems, and individualized postoperative care, encompassing early mobilization, tailored pain management, and close monitoring of metabolic parameters. Despite advancements, knowledge gaps remain, particularly regarding sarcopenic obesity and the long-term impact of preoperative dietary interventions. Future research should focus on refining minimally invasive techniques, integrating personalized medicine, and exploring innovative perioperative protocols to address obesity-related risks effectively. By fostering a multidisciplinary approach, this review underscores the necessity for targeted interventions to enhance outcomes and improve the quality of care for patients with obesity undergoing gastrointestinal cancer surgery.</div></div>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":"114 ","pages":"Pages 138-149"},"PeriodicalIF":12.1,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The microbiome-immune cell interaction network: Advancing tumor immunotherapy 微生物组-免疫细胞相互作用网络:推进肿瘤免疫治疗
IF 12.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-06-24 DOI: 10.1016/j.semcancer.2025.06.009
Wei Liu, Zhou Lan, Zhenzi Lin, Yuyue Zhao, Junxiang Lian, Guangtao Yu
Tumor immunotherapy has achieved revolutionary advancements; however, owing to the complex interplay of multiple intrinsic and extrinsic tumor factors, the patient response rate remains suboptimal. Recent research has emphasized the pivotal role of microbiome in tumor progression. Under normal physiological conditions, microbiome enter orally and colonize sites such as the oral and intestinal mucosa, establishing a dynamic microbiome equilibrium that participates in essential physiological processes, including host metabolism and immune regulation. However, in pathological states, including dysbiosis, tumor initiation, or compromised mucosal barrier function, the microbiome can penetrate the mucosal barrier, infiltrate tumor tissues, and engage in intricate direct or indirect interactions with immune cells. These interactions play a pivotal role in reshaping the tumor immune microenvironment and modulating the host's anti-tumor immune response. This review elaborate the regulatory mechanisms involved in direct and indirect interactions between microbiome and immune cells within tumors, and their implications for tumor immunotherapy. We discuss the external factors that impact these interactions and outline the potential use of engineered bacteria in cancer treatment. From the perspective of the interaction network between microbiomes and immune cells, this review elucidates the mechanisms and potential of microbiomes in tumor immunotherapy, offering new insights and potential targets for innovative strategies in tumor prevention and treatment.
肿瘤免疫治疗取得革命性进展;然而,由于多种内在和外在肿瘤因素的复杂相互作用,患者的反应率仍然不理想。最近的研究强调了微生物组在肿瘤进展中的关键作用。在正常生理条件下,微生物组通过口腔进入机体并定植于口腔和肠道粘膜等部位,形成动态的微生物组平衡,参与机体代谢和免疫调节等重要生理过程。然而,在病理状态下,包括生态失调、肿瘤起始或粘膜屏障功能受损,微生物组可以穿透粘膜屏障,浸润肿瘤组织,并与免疫细胞进行复杂的直接或间接相互作用。这些相互作用在重塑肿瘤免疫微环境和调节宿主抗肿瘤免疫反应中起着关键作用。本文综述了肿瘤内微生物群与免疫细胞直接和间接相互作用的调控机制及其对肿瘤免疫治疗的启示。我们讨论了影响这些相互作用的外部因素,并概述了工程细菌在癌症治疗中的潜在用途。本文从微生物组与免疫细胞相互作用网络的角度,阐述微生物组在肿瘤免疫治疗中的作用机制和潜力,为肿瘤预防和治疗的创新策略提供新的见解和潜在的靶点。
{"title":"The microbiome-immune cell interaction network: Advancing tumor immunotherapy","authors":"Wei Liu,&nbsp;Zhou Lan,&nbsp;Zhenzi Lin,&nbsp;Yuyue Zhao,&nbsp;Junxiang Lian,&nbsp;Guangtao Yu","doi":"10.1016/j.semcancer.2025.06.009","DOIUrl":"10.1016/j.semcancer.2025.06.009","url":null,"abstract":"<div><div>Tumor immunotherapy has achieved revolutionary advancements; however, owing to the complex interplay of multiple intrinsic and extrinsic tumor factors, the patient response rate remains suboptimal. Recent research has emphasized the pivotal role of microbiome in tumor progression. Under normal physiological conditions, microbiome enter orally and colonize sites such as the oral and intestinal mucosa, establishing a dynamic microbiome equilibrium that participates in essential physiological processes, including host metabolism and immune regulation. However, in pathological states, including dysbiosis, tumor initiation, or compromised mucosal barrier function, the microbiome can penetrate the mucosal barrier, infiltrate tumor tissues, and engage in intricate direct or indirect interactions with immune cells. These interactions play a pivotal role in reshaping the tumor immune microenvironment and modulating the host's anti-tumor immune response. This review elaborate the regulatory mechanisms involved in direct and indirect interactions between microbiome and immune cells within tumors, and their implications for tumor immunotherapy. We discuss the external factors that impact these interactions and outline the potential use of engineered bacteria in cancer treatment. From the perspective of the interaction network between microbiomes and immune cells, this review elucidates the mechanisms and potential of microbiomes in tumor immunotherapy, offering new insights and potential targets for innovative strategies in tumor prevention and treatment.</div></div>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":"114 ","pages":"Pages 128-137"},"PeriodicalIF":12.1,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144480164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipids and lipoproteins in the interstitial tissue fluid regulate the formation of dysfunctional tissue-resident macrophages: Implications for atherogenic, tumorigenic, and obesogenic processes 间质组织液中的脂质和脂蛋白调节功能失调的组织巨噬细胞的形成:与动脉粥样硬化、致瘤性和致肥过程的关系。
IF 12.1 1区 医学 Q1 ONCOLOGY Pub Date : 2025-06-20 DOI: 10.1016/j.semcancer.2025.06.008
Miriam Lee-Rueckert , Matti Jauhiainen , Petri T. Kovanen , Joan Carles Escolà-Gil
An inflammatory and lipid-enriched tissue microenvironment is a common characteristic of the extracellular niches of affected tissues in atherosclerosis, cancer, and obesity. These respective interstitial environments appear to be induced by infiltration of plasma lipids and early local recruitment of monocyte-derived macrophages. In the tissue niches, the macrophages display remarkable phenotypic and functional plasticity and exert multifaceted roles in tissue homeostasis. Multiple local signaling events contribute to the phenotypic polarization of the tissue-resident macrophages into M1-like, M2-like, and multiple mixed subpopulations. This study aims to review and compare the roles of lipids and lipoproteins in shaping the inflammatory and lipid-enriched microenvironments of atherosclerotic arterial intima, malignant tumors, and obese adipose tissue, so generating dysfunctional macrophages. Circulating lipoprotein-bound lipids and albumin-bound fatty acids can cross the vascular endothelial barrier and infiltrate the interstitial fluids, resulting in variable levels of plasma-derived lipids, notably low-density lipoproteins (LDL), high-density lipoproteins (HDL), and locally generated small lipid-poor HDL species (preβ-HDL). Whilst LDL particles mainly supply liver-derived cholesterol to the cells of peripheral tissues, HDL particles can promote the reverse transfer of cellular cholesterol into the circulation and ultimately via the liver to the gut for its fecal excretion. Thus, the LDL/HDL ratio in the interstitial fluids can either promote or prevent cholesterol accumulation in the tissue-resident macrophages. Various types of peripheral cells modify interstitial LDL and HDL particles by oxidation, proteolysis, lipolysis, aggregation, or fusion, rendering them dysfunctional. By engulfing excessive amounts of extracellular lipids and modified LDL particles in such lipid-rich microenvironments, macrophages can become dysfunctional, a typical example being the atherosclerotic arterial intima. Similarly, tissue microenvironments characteristic of several malignant tumors and the obese adipose tissue are rich in triglyceride (TG)-rich lipoproteins and free fatty acids, inducing accumulation of TG and glycerophospholipids in the intracellular lipid droplets of macrophages. The lipid-loaded macrophages are currently considered novel markers for diagnosis and selective therapeutic targets not only in the arterial intima but also in malignant tumors and obese adipose tissue. Together, the available data identify potential roles of lipids and lipoproteins present in the interstitial fluids of the atherosclerotic arterial intima, malignant tumors, and obese adipose tissue in the generation of distinct lipid-loaded macrophage subpopulations and suggest their contributory roles in the development and progression of atherosclerosis, cancer, and obesity, the three major health concerns worldwide.
炎症和富含脂质的组织微环境是动脉粥样硬化、癌症和肥胖症中受影响组织的细胞外生态位的共同特征。这些不同的间质环境似乎是由血浆脂质浸润和单核细胞源性巨噬细胞的早期局部募集诱导的。在组织壁龛中,巨噬细胞表现出显著的表型和功能可塑性,并在组织稳态中发挥多方面的作用。多个局部信号事件导致组织内巨噬细胞表型分化为m1样、m2样和多个混合亚群。本研究旨在回顾和比较脂质和脂蛋白在形成动脉粥样硬化内膜、恶性肿瘤和肥胖脂肪组织的炎症和富含脂质的微环境,从而产生功能失调的巨噬细胞中的作用。循环脂蛋白结合的脂质和白蛋白结合的脂肪酸可以穿过血管内皮屏障并浸润间质液,导致血浆来源的脂质水平变化,特别是低密度脂蛋白(LDL)、高密度脂蛋白(HDL)和局部生成的小脂质贫HDL物种(前β-HDL)。LDL颗粒主要向外周组织细胞提供肝源性胆固醇,而HDL颗粒可以促进细胞胆固醇逆向转移进入循环,最终通过肝脏进入肠道粪便排泄。因此,间质液中的LDL/HDL比值可以促进或阻止组织内巨噬细胞中的胆固醇积累。各种类型的外周细胞通过氧化、蛋白水解、脂解、聚集或融合改变间质LDL和HDL颗粒,使其功能失调。在这种富含脂质的微环境中,巨噬细胞通过吞噬过量的细胞外脂质和修饰的LDL颗粒而变得功能失调,典型的例子是动脉粥样硬化的动脉内膜。同样,一些恶性肿瘤和肥胖脂肪组织的组织微环境也富含富含甘油三酯(TG)的脂蛋白和游离脂肪酸,从而诱导巨噬细胞内脂滴中TG和甘油磷脂的积累。脂质巨噬细胞不仅在动脉内膜,而且在恶性肿瘤和肥胖脂肪组织中都被认为是诊断和选择性治疗的新标志物。总之,现有数据确定了存在于动脉粥样硬化动脉内膜、恶性肿瘤和肥胖脂肪组织的间质液中的脂质和脂蛋白在产生不同的脂质负载巨噬细胞亚群中的潜在作用,并表明它们在动脉粥样硬化、癌症和肥胖这三大全球健康问题的发生和进展中所起的促进作用。
{"title":"Lipids and lipoproteins in the interstitial tissue fluid regulate the formation of dysfunctional tissue-resident macrophages: Implications for atherogenic, tumorigenic, and obesogenic processes","authors":"Miriam Lee-Rueckert ,&nbsp;Matti Jauhiainen ,&nbsp;Petri T. Kovanen ,&nbsp;Joan Carles Escolà-Gil","doi":"10.1016/j.semcancer.2025.06.008","DOIUrl":"10.1016/j.semcancer.2025.06.008","url":null,"abstract":"<div><div>An inflammatory and lipid-enriched tissue microenvironment is a common characteristic of the extracellular niches of affected tissues in atherosclerosis, cancer, and obesity. These respective interstitial environments appear to be induced by infiltration of plasma lipids and early local recruitment of monocyte-derived macrophages. In the tissue niches, the macrophages display remarkable phenotypic and functional plasticity and exert multifaceted roles in tissue homeostasis. Multiple local signaling events contribute to the phenotypic polarization of the tissue-resident macrophages into M1-like, M2-like, and multiple mixed subpopulations. This study aims to review and compare the roles of lipids and lipoproteins in shaping the inflammatory and lipid-enriched microenvironments of atherosclerotic arterial intima, malignant tumors, and obese adipose tissue, so generating dysfunctional macrophages. Circulating lipoprotein-bound lipids and albumin-bound fatty acids can cross the vascular endothelial barrier and infiltrate the interstitial fluids, resulting in variable levels of plasma-derived lipids, notably low-density lipoproteins (LDL), high-density lipoproteins (HDL), and locally generated small lipid-poor HDL species (preβ-HDL). Whilst LDL particles mainly supply liver-derived cholesterol to the cells of peripheral tissues, HDL particles can promote the reverse transfer of cellular cholesterol into the circulation and ultimately via the liver to the gut for its fecal excretion. Thus, the LDL/HDL ratio in the interstitial fluids can either promote or prevent cholesterol accumulation in the tissue-resident macrophages. Various types of peripheral cells modify interstitial LDL and HDL particles by oxidation, proteolysis, lipolysis, aggregation, or fusion, rendering them dysfunctional. By engulfing excessive amounts of extracellular lipids and modified LDL particles in such lipid-rich microenvironments, macrophages can become dysfunctional, a typical example being the atherosclerotic arterial intima. Similarly, tissue microenvironments characteristic of several malignant tumors and the obese adipose tissue are rich in triglyceride (TG)-rich lipoproteins and free fatty acids, inducing accumulation of TG and glycerophospholipids in the intracellular lipid droplets of macrophages. The lipid-loaded macrophages are currently considered novel markers for diagnosis and selective therapeutic targets not only in the arterial intima but also in malignant tumors and obese adipose tissue. Together, the available data identify potential roles of lipids and lipoproteins present in the interstitial fluids of the atherosclerotic arterial intima, malignant tumors, and obese adipose tissue in the generation of distinct lipid-loaded macrophage subpopulations and suggest their contributory roles in the development and progression of atherosclerosis, cancer, and obesity, the three major health concerns worldwide.</div></div>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":"114 ","pages":"Pages 104-127"},"PeriodicalIF":12.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Seminars in cancer biology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1